Advertisement
Advanced Search
< Previous Article
Next Article >
September 2009Volume 27, Issue 7, Pages 903.e1–903.e3
Switch to Standard ViewSwitch to Enhanced View

Trastuzumab (Herceptin)–associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review

Chung-Ming Tu
x
Chung-Ming Tu
, MD
Division of Cardiology Department of Medicine, Song-Shan Armed Forces General Hospital, Taipei, Taiwan, R.O.C.
Division of Cardiology Department of Medicine, Tri-Service General Medical Center, Taipei, Taiwan, R.O.C.
Kai-Ming Chu
x
Kai-Ming Chu
, MD, PhD
Division of Cardiology Department of Medicine, Tri-Service General Medical Center, Taipei, Taiwan, R.O.C.
Shin-Ping Yang
x
Shin-Ping Yang
, MD, PhD
Division of Cardiology Department of Medicine, Tri-Service General Medical Center, Taipei, Taiwan, R.O.C.
Shu-Mung Cheng
x
Shu-Mung Cheng
, MD, PhD
Division of Cardiology Department of Medicine, Tri-Service General Medical Center, Taipei, Taiwan, R.O.C.
Wen-been Wang
x
Wen-been Wang
, MD
Division of Cardiology Department of Medicine, Song-Shan Armed Forces General Hospital, Taipei, Taiwan, R.O.C.
Division of Cardiology Department of Medicine, Tri-Service General Medical Center, Taipei, Taiwan, R.O.C.
DOI: http://dx.doi.org/10.1016/j.ajem.2008.11.012

References

  1. [1]Slamon, DJ, Leyland-Jones, B, Shak, S et al, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
  2. [2]Romond, EH, Perez, EA, Bryant, J et al, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684.
  3. [3]Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B et al, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
  4. [4]Joensuu, H, Kellokumpu-Lehtinen, PL, Bono, P et al, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820.
  5. [5]Slamon, D, Eiermann, W, Robert, N et al, Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94:S5 ([abstr 1]).
    • [6]Yeon, CH, Pegram, MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23:391–409.
    • [7]Suter, TM, Cook-Bruns, N, Barton, C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13:173–183.
    • [8]Wong, SF. Trastuzumab and cardiotoxicity: weighing the risks. Am J Health Syst Pharm. 2006;63:525.
    • [9]Schneider, JW, Chang, AY, Garratt, A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol. 2002;29:22–28.
    • [10]Ewer, MS, Vooletich, MT, Durand, J-B, Woods, ML, Davis, JR, Valero, V et al, Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826.
    • [11]Sliwkowski, MX, Lofgren, JA, Lewis, GD et al, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60–70.
    © 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
    Access this article on
    ScienceDirect
    Visit ScienceDirect to see if you have access via your institution.

    Article Tools

    Related Articles

    Searching for related articles..

    Advertisement
    < Previous Article
    Next Article >
    September 2009Volume 27, Issue 7, Pages 903.e1–903.e3